z-logo
Premium
Temporal Trends in Mucocutaneous Findings Among Human Immunodeficiency Virus 1‐Infected Children in a Population‐Based Cohort
Author(s) -
Sturt Amy S.,
Anglemyer Andrew,
Berk David R.,
Maldonado Yvonne A.
Publication year - 2012
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.12020
Subject(s) - medicine , mucocutaneous zone , cohort , pediatrics , population , cohort study , prospective cohort study , disease , environmental health
The objective of the study was to determine the prevalence of pediatric human immunodeficiency virus 1 ( HIV ‐1) mucocutaneous manifestations in the era of highly active antiretroviral therapy ( HAART ). We conducted population‐based, prospective, multicenter pediatric HIV ‐1 surveillance in 276 children with perinatally acquired HIV ‐1 from 1988 to 2009. Centers for Disease Control and Prevention ( CDC )‐defined HIV‐1 related mucocutaneous conditions among the 276 children were: category A ( n  = 152), B ( n  = 60), and C ( n  = 1). Nearly half of the category A and B diagnoses (43.4% [66/152] and 35.0% [21/60], respectively) occurred in the first year of life, with 59.2% (90/152) and 61.7% (37/60), respectively, occurring in the first 2 years of life. The most frequent infectious diagnosis was oropharyngeal thrush ( n  = 117, 42.4%); the most common inflammatory diagnosis was diaper dermatitis ( n  = 71, 25.7%). There was a temporal decline in the prevalence of A (pre‐ HAART cohort, 123; post‐ HAART cohort, 29; p < 0.01) and B (pre‐ HAART , 55; post‐ HAART , 5; p < 0.01) mucocutaneous diagnoses. In children with perinatal HIV ‐1, there was a significant decline in CDC category A and B mucocutaneous diagnoses by temporal cohort, consistent with the introduction of antiretroviral medications and HAART . Clinical category A and B mucocutaneous diagnoses were most common in the first 2 years of life, emphasizing the importance of early HIV ‐1 testing and HAART initiation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here